Poly (ADP-ribose) polymerases or PARP inhibitors are medical drugs used primarily for the treatment of cancer. These drugs work by inhibiting the action of PARP enzymes that are involved in DNA repair. In the presence of DNA damage, PARP enzymes signals other proteins involved in DNA repair. By inhibiting PARP enzymes, DNA damage caused by chemotherapy or radiation therapy is not repaired, leading to cell death. PARP inhibitors are increasingly being used as maintenance therapy for ovarian cancer and as first-line therapy in combination with chemotherapy for breast cancer. They help in improving treatment outcomes and prolonging remission periods in cancer patients.
The global PARP inhibitor market is estimated to be valued at US$ 6.13 billion in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing demand for PARP inhibitors from breast cancer treatment is a major driver bolstering the growth of this market. According to the American Cancer Society, breast cancer is the most common cancer among women worldwide. PARP inhibitors have shown promising results in improving treatment response when used as part of first-line therapy with chemotherapy for aggressive breast cancers. Another factor fueling the market growth is the rising cases of ovarian cancer globally. PARP inhibitors are one of the standard maintenance therapies available for relapsed ovarian cancer patients. The high efficacy and tolerability of these drugs in increasing progression free survival in ovarian cancer continue to encourage new product approvals and overall usage. Sustained research efforts to discover new PARP inhibitors and expand application scope will further aid market expansion over the forecast period.
Segment Analysis
The PARP inhibitor market is dominated by the ovarian cancer sub-segment. According to recent statistics, ovarian cancer accounts for over 50% of market revenue, owing to a high incidence rate and high treatment cost of PARP inhibitors in ovarian cancer. PARP inhibitors such as niraparib, olaparib and rucaparib have been approved for later lines of treatment in recurrent ovarian cancer and are frequently used.
PEST Analysis
Political: Regulatory bodies globally are encouraging research and development of precision cancer medicines. Approvals for new drug applications of PARP inhibitors have increased in major regions.
Economic: The high cost of PARP inhibitors restricts their usage in developing nations. However, partnership deals between pharmaceutical companies and government organizations are improving accessibility.
Social: Increased awareness about targeted cancer therapies and availability of clinical trial data is positively impacting the adoption of PARP inhibitors. However, high treatment expenditure remains a challenge.
Technological: Continuous research into biomarkers and combination therapies has increased the clinical efficacy of PARP inhibitors. Companion diagnostics are assisting in identifying patients most likely to benefit.
Key Takeaways
The Global PARP Inhibitor Market is expected to witness high growth at a CAGR of 11% during the forecast period of 2023 to 2030.
Regional analysis shows North America currently dominates with over 45% market share due to large patient volumes and favorable reimbursements. Europe is also a major region bolstered by government support for cancer R&D.
Key players operating in the PARP inhibitor market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Clovis Oncology, Inc. AstraZeneca’s Lynparza and GlaxoSmithKline’s Zejula are commonly prescribed PARP inhibitors. GlaxoSmithKline has strengthened its portfolio through acquisition of Tesaro, adding Zejula and pipeline assets. Partnerships between pharmaceutical companies and clinical trials are enabling faster approvals and access to newer PARP inhibitors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
